A Blood-Saving Tool With an Unexpected Risk: Cell Saver Ratio and Pulmonary Embolism After Spine Deformity Surgery
A 13-center North American study finds that patients who receive a high proportion of their blood loss back via cell saver technology face more than six times the risk of pulmonary embolism — independent of surgical complexity.
OPENING SUMMARY
Cell saver technology — which collects, filters, and returns a patient's own blood lost during surgery — has long been considered a safe and beneficial component of blood management in complex spine surgery. By reducing reliance on donor blood transfusions, it is widely used in adult spinal deformity procedures where blood loss can be substantial. This study does not challenge the value of cell saver technology broadly, but it raises an important and previously unrecognized question: does the ratio of how much salvaged blood is returned relative to how much was lost matter for patient safety? The findings suggest it does — and the implications for perioperative blood management in ASD surgery deserve careful attention.
STUDY SNAPSHOT
Study type – Multicenter observational prospective study (retrospective analysis)
Number of patients – 406
Number of centers – 13 spinal deformity centers in North America
High CS:EBL group (≥0.33) – 43 patients (10.6%)
Low CS:EBL group (<0.33) – 363 patients (89.4%)
Primary outcomes – Cardiopulmonary and renal complications
Key finding – Pulmonary embolism within 30 days
Statistical model – Multivariable logistic regression adjusting for group differences; AUC 0.92
Published in – Journal of Neurosurgery: Spine
PMID – 41569673
DOI – 10.3171/2025.8.SPINE25583
WHY THIS MATTERS
Blood management is one of the most consequential perioperative considerations in adult spinal deformity surgery. These are long, complex procedures that frequently involve significant blood loss, and the strategies used to manage that loss — including cell saver autotransfusion, allogeneic blood transfusion, and pharmacologic agents — all carry their own risk and benefit profiles.
Cell saver autotransfusion has been widely adopted in part because it is perceived as inherently safer than donor blood — returning a patient's own cells avoids the risks of transfusion reactions and bloodborne pathogen exposure. But the assumption that more cell saver return is always better has not been rigorously tested in complex ASD surgery. This study is among the first to examine not just whether cell saver was used, but the ratio of salvaged blood returned to total blood lost — and to ask whether that ratio independently predicts serious postoperative complications.
The answer has meaningful implications for how anesthesiologists and spine surgeons approach intraoperative blood management decisions, particularly in older patients undergoing less extensive but still complex procedures.
KEY FINDINGS
1. A high CS:EBL ratio was associated with more than six times the risk of pulmonary embolism. Patients whose ratio of cell saver return to estimated blood loss was 0.33 or greater had a pulmonary embolism rate of 9.3% within 30 days of surgery, compared to 1.4% in patients with a lower ratio — a statistically significant difference (p=0.0093). On multivariable logistic regression adjusting for the significant differences between groups, a CS:EBL ratio ≥0.33 remained an independent risk factor for PE, with an odds ratio of 6.57 (95% CI 1.75–24.66). The statistical model demonstrated excellent diagnostic performance, with an area under the receiver operating characteristic curve of 0.92.
2. The elevated PE risk was independent of surgical complexity and blood loss. This is perhaps the most important nuance of the finding. Patients in the high CS:EBL group actually had less total blood loss (mean 1,048 mL vs. 1,696 mL), fewer instrumented levels (mean 12.2 vs. 14.1), fewer osteotomies, and less coronal correction than those in the low CS:EBL group. In other words, the high-ratio patients were not the most complex surgical cases — yet they had substantially higher PE rates. After adjusting for these differences statistically, the CS:EBL ratio itself remained the independent driver of risk.
3. High CS:EBL patients were older and received less allogeneic blood despite similar overall transfusion rates. Patients with a CS:EBL ratio ≥0.33 were significantly older (mean 66.2 vs. 58.9 years) and received fewer units of packed red blood cells, fresh frozen plasma, and platelets intraoperatively — suggesting that in these patients, cell saver return was substituting for allogeneic transfusion more completely than in the low-ratio group. The combination of older age and higher proportional cell saver return may be relevant to understanding the underlying mechanism.
4. Overall cardiopulmonary and renal complication rates did not differ between groups. When cardiopulmonary complications were analyzed as a combined category, no significant difference was found between groups. The PE signal only emerged when complications were stratified by specific type — underscoring the importance of granular outcome reporting in complex surgical populations rather than relying solely on aggregate complication rates.
5. The findings prompt a re-evaluation of cell saver use assumptions. The study's authors explicitly state that the findings support re-evaluating salvaged red blood cell use in this patient population based on perceived benefits. While cell saver technology remains an important tool, the assumption that maximizing its use is universally beneficial may warrant reconsideration — particularly in older patients with lower blood loss where the CS:EBL ratio is most likely to be elevated.
PRACTICAL IMPLICATIONS
The CS:EBL ratio may be a simple, calculable perioperative risk metric. Both cell saver return volume and estimated blood loss are routinely documented in ASD surgery. The ratio between them is straightforward to calculate and, based on this study, may carry meaningful prognostic information about PE risk. If validated in future studies, this could become a practical intraoperative or early postoperative flag for heightened VTE surveillance.
Older patients with lower blood loss may warrant particular attention. The profile of the high CS:EBL patient in this study — older, less blood loss, shorter fusion, less osteotomy — is not the stereotypical high-risk complex deformity case. This finding suggests that PE risk in ASD surgery may not track straightforwardly with surgical complexity, and that risk stratification models should account for blood management variables in addition to procedural ones.
Enhanced postoperative VTE surveillance may be warranted in high CS:EBL patients. Given the substantially higher PE rate in the high CS:EBL group — 9.3% versus 1.4% — clinicians may wish to consider more vigilant postoperative monitoring for venous thromboembolism in patients where the ratio of returned salvaged blood to total blood loss was high, pending further validation of this finding.
Future research should investigate the biological mechanism. The abstract does not propose a definitive explanation for why a high CS:EBL ratio would independently elevate PE risk. Potential mechanisms — including reintroduction of activated clotting factors, cellular debris, or other procoagulant material via salvaged blood — are plausible hypotheses that future studies should investigate directly. Understanding the mechanism will be important for determining whether the risk can be mitigated by modifying cell saver processing protocols or transfusion thresholds.
CONCLUSION
This study identifies a previously unrecognized and clinically significant association between the ratio of cell saver return to estimated blood loss and the risk of pulmonary embolism after adult spinal deformity surgery. The finding is notable both for its statistical robustness — confirmed on multivariable analysis with excellent model performance — and for its counterintuitive profile: the elevated risk appeared in older patients with less surgical complexity, not in the most medically challenging cases. For a field that has long viewed cell saver autotransfusion as straightforwardly beneficial, these findings represent an important prompt to examine blood management assumptions more carefully — and to ensure that the tools used to protect patients intraoperatively do not introduce risks that have gone unrecognized.
READ THE FULL STUDY
